Articles & ProceduresOffice LocationsPatient InformationHospital AffilliationsPrivacy PolicyFormsServicesJobs

Norman D. Jaffe, MD, FACC, FASNC

EDUCATION:

  • 1982 - University of Maryland B.S, in Biology
  • 1988 - Tel Aviv University, Israel M.D.

POSTDOCTORAL TRAINING:
           
Internship and Residency:

  • 1988 – 1991 - Internal Medicine, Danbury Hospital, Danbury, CT

Fellowships:

  • 1991 – 1994
    • Cardiology
      • Boston VAMC/Boston University, Boston, MA

PRINCIPAL CLINICAL AND HOSPITAL SERVICE RESPONSIBILITIES:

  • 1994 – Present
    • Non-Invasive Clinical Cardiologist
      • Onondaga Hill Cardiovascular Group, PC
      • Community General Hospital, Syracuse, N.Y.
  • 1994 – Present
    • Radiation Safety Officer
      • Onondaga Hill Cardiovascular Group, PC, Syracuse, N.Y.

LICENSURE AND CERTIFICATION:

  • 1993 
    • Board Certification - Internal Medicine. Exp. 2003.

  • 1997
    • Board Certification - Cardiovascular Disease.

  • 1998
    • Fellow-American College of Cardiology

  • 2008
    • Recertification - Cardiovascular Disease

  • 2009
    • Board Certification - Nuclear Cardiology

  • 2010
    • Fellow-American Society of Nuclear Cardiology

  • Present
    • New York, Hawaii State Licenses

RESEARCH:

  • 2003-2007
    • National Principal Investigator. Vitatron VIBRANT Registry.
      Shoreview, MN

  • 2001-2004
    • Principal Investigator.  Vitatron’s Selection aFM Registry.
      Community General       Hospital, Syracuse, NY

  • 1999
    • Principal Investigator ASSENT – 3. (Acute Myocardial Infarction Study).  Community General Hospital, Syracuse, NY
  • 1992 – 1993
    • Co-Investigator for PROFILE heart failure trials,
      Boston VA Medical Center, Boston, MA

    • Co-Investigator for V-HeFT heart failure trials,
      Boston VA Medical Center, Boston, MA

    • Co-investigator  VA-HIT Study.
      Boston VA Medical Center, Boston MA
  • 1989 – 1991
    • Site Investigator for TIMI2B/UNSA thrombolytic trials,
      Danbury Hospital, Danbury, CT
  • 1984 – 1986
    • Research Assistant, Oncology Department,
      Long Island Jewish Medical Center, N.Y.
  • 1982 – 1984
    • Research Technician/ Cell Biology, Oncology Department.
      Washington       VAMC, Washington, D.C.

AWARDS AND HONORS :

  • 1995, 1997, 2000, 2003
    • Teacher of the Year,
      • St. Joseph’s Hospital Health Center, Family Practice Residency Program

BIBLIOGRAPHY:

Publications:

  • Jaffe ND, Boden WE. Spontaneous transient, inverted U waves as initialelectrocardiographic manifestations of unstable angina. Am. Heart J.,
    May, 1995

  • Citron ML, Jaffe ND, Hamberger AW, Linblat A, Yenson A, Banda FB, CohenMH. CANCER.
    June 15, 1986; 71(3): 2357-2362.

  • Cohen MH, Johnston-Early A, Hood MA, McKenzie M, Citron, ML, Jaffe ND,     Krasnow SR. CANCER TREATMENT REPORTS.
    November, 1985; 69(11):     1625-1626.

  • Citron ML, Jaffe ND, Krasnow SR, Johnston-Anderson A, Cohen MH.Randomized Comparison of the Timing of Antiemetics for Chemotherapy-
    Induced Nausea and Vomiting. Submitted.

Abstracts:

  • Jaffe ND, Reiter M, Kawanishi D, Caceres L, Singh V, Lung T and Leitschuh J. What Drives Therapy Change: VIBRANT Registry Final Results.  Europace: June, 2007.  Abstract # 40827.

  • Jaffe ND, Reiter M, Kawanishi D, Caceres L, Singh V, Lung T and Leitschuh     J.Comparison of Final Results of Two Registries Evaluation the Use of           Therapy Advisor in C-Series  Pacemakers. 
    Europace: June, 2007.  Abstract # 40840.

  • Reitner M, Jaffe ND, Kawanishi D, Caceres L, Singh V, Lung T and Leitschuh   J.Diagnostic Messages and Programming Recommendations in a                     Pacemaker Advisory System-Frequency and Clinical Correlation. 
    Europace: June, 2007.     Abstract # 40903.

  • Jaffe ND, Reiter M, Kawanishi D, Caceres L, Singh V, Lung T and Leitschuh J.
    Comparison of Final Results of Two Registries Evaluation the Use of Therapy
    Advisor in C-Series Pacemakers.  Heart Rhythm Society:
    May, 2007.      Abstract #3501.

  • Jaffe ND and Lung TH.  VIBRANT registry Interim Results:  Effectiveness of
    Advanced Diagnostics in Early Follow-up after Elective Pacemaker Replacement. 
    Europace: June, 2005.  Abstract # 835.

  • Jaffe ND, Lung TH and Charles RG.  Comparison of Interim Results of Two
    Registries Evaluating the Use of Vitatron’s Therapy Advisor.  Europace: 
    June 2005.  Abstract # 201.

  • Jaffe ND and Kotch A. Serum Theophylline Levels in COPD Patients During the Conversion from I.V. Aminophylline to P.O. Theo-Dur.
    November, 1991.     Abstract #429.

  • Citron ML, Krasnow SR, Alhashimi M, Jaffe ND, Johnston-Early A, Hood MA,
    Franklin r, Cohen MH. Time Interval Between Starting an Antiemetic and
    Giving Chemotherapy: Absence of Beneficial Effect in Controlling
    Chemotherapy-Induced Nausea and Vomiting with Earlier Administration of
    Droperidol in a Phase 3 Placebo Controlled, Double Blind, Crossover Study.
    ASCO-AACR.
    March, 1989. Abstract #1283.

  • Citron ML, Jaffe ND, Hamberger AW, Yenson A, Banda FB, Cohen MH. A
    Comparison of Three Methods for Soft Agar Cloning. ASCO-AACR.
    May,     1984. Abstract #1489.